Claims

1. Reagent for use in diagnostics and/or therapy, **charact ris d in that**, at at least two spatially separated positions on a cell-bound or soluble molecule, it enters into interactions with the latter or the nucleic acid coding for this.

2. Reagent according to Claim 1, **characterised in that** it covers at least one antigen binding domain.

3. Reagent according to one of the Claims 1 or 2, **characterised in that** it is selected from antibodies, antibody fragments, chimerized antibodies, humanised antibodies, single chain (sc)Fv fragments, scT-cell receptor (TCR) fragments, hybrid scFv/scTCR fragments, RNA or DNA aptamers and RNA or DNA Spiegelmers.

4. Reagent according to one of the Claims 1 to 3, **characterised in that** it binds to CD30.

5. Reagent according to one of the Claims 1 to 4, **characterised in that** it binds to an epitope with the core sequence CEPDY.

6. Reagent according to one of the Claims 1 to 5, **characterised in that** the reagent is a chimerized antibody or a fragment of the same.

7. Reagent according to one of the Claims 1 to 6, **characterised in that** the reagent is available from a culture medium of the cell DSZ1 stored at the German Microorganisms Collection (DSM) under the number DSM ACC2548.

8. Reagent according to one of the Claims 1 to 7, **characterised in that** it also contains a toxin and/or a marking.

9. Reagent according to Claim 8, **characterised in that** it is linked peptidically or via linker molecules with toxic proteins or with enzymes or proenzymes.

10. Reagent according to Claim 9, **characterised in that** it is linked with toxins in the form of ribosome-inactivating proteins.

11. Reagent according to Claim 9, **characterised in that** it is linked with enzymes from the group of the phosphodiesterases.

12. Reagent according to Claim 9, **characterised in that** it is linked directly or via a linker molecule covalently or conjugated with radioactive isotopes.

13. Reagent according to Claim 12, **characterised in that** the radioactive isotopes are selected from the group consisting of indium, iodine, yttrium, technetium, rhenium, copper and lutetium.

14. Reagent according to Claims 8 to 9, **characterised in that** it is linked directly or via linker molecules covalently or conjugated with photactivatable compounds.

15. Cell which produces a reagent according to one of the Claims 1 to 7.

16. Cell according to Claim 15, **characterised in that** it contains a recombinant DNA which codes for the reagent or a part thereof.

17. Cell according to one of the Claims 15 or 16, **characterised in that** it shows essential features of the cell as stored at the DSM under no. DSM ACC2548, especially the ability to give off the antibody in a considerably higher concentration into the medium than comparable cells.

18. Cell according to one of the Claims 15 or 16, **characterised in that** it was stored at the DSM under the no. DSM ACC2548.

19. Method for the diagnosis especially of tumours and inflammatory diseases, **characterised in that** a sample from the test person is brought into contact with a

reagent according to one of the Claims 1 to 14 and the extent of the reaction of the reagent with the sample is determined.

20. Method for the diagnosis of diseases, **characterised in that** the diagnosis is carried out in vivo and that it covers, for example, a scintigraphy.

21. Use of a reagent according to one of the Claims 1 to 14 for the treatment of tumours, inflammatory, inflammatory-allergic and/or autoimmune diseases.

22. Use according to Claim 21, **characterised in that** the tumour is a lymphoma or embryonal carcinoma.

23. Use according to Claim 22, **characterised in that** the lymphoma is a CD30-positive lymphoma.

24. Use according to Claim 23, **characterised in that** the CD30-positive lymphoma is a Hodgkin's lymphoma, an anaplastic large-cell lymphoma or an acute or lymphomatous form of adult T-cell leukaemia.

25. Use according to one of the Claims 21 to 24, **characterised in that** 10 to 1000 mg/m^2 body surface of reagent is dispensed.

26. Use according to Claim 25, **characterised in that** 20 to 400 mg/m^2 body surface of reagent is dispensed.

27. Use according to one of the Claims 21 to 26, **characterised in that** the reagent is dispensed i.v.

28. Use of a reagent according to one of the Claims 1 to 14 for the production of a composition for the suppression or avoidance of a rejection reaction and/or a graft-versus-host reaction in the transplantation of organs, bone marrow or stem cells.

29. Pharmaceutical composition containing a reagent according to one of the Claims 1 to 14.

30. Kit for the diagnosis in particular of tumours, especially CD30-positive neoplasies, and inflammatory diseases, containing a reagent according to one of the Claims 1 to 14 together with instructions for use for the reagent.